252 related articles for article (PubMed ID: 21784901)
41. Outcome of C3 glomerulopathy patients: largest single-centre experience from South Asia.
Kumar A; Nada R; Ramachandran R; Rawat A; Tiewsoh K; Das R; Rayat CS; Gupta KL; Vasishta RK
J Nephrol; 2020 Jun; 33(3):539-550. PubMed ID: 31820418
[TBL] [Abstract][Full Text] [Related]
42. Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy.
Levine AP; Chan MMY; Sadeghi-Alavijeh O; Wong EKS; Cook HT; Ashford S; Carss K; Christian MT; Hall M; Harris CL; McAlinden P; Marchbank KJ; Marks SD; Maxwell H; Megy K; Penkett CJ; Mozere M; Stirrups KE; Tuna S; Wessels J; Whitehorn D; ; ; Johnson SA; Gale DP
J Am Soc Nephrol; 2020 Feb; 31(2):365-373. PubMed ID: 31919107
[TBL] [Abstract][Full Text] [Related]
43. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.
Leroy V; Fremeaux-Bacchi V; Peuchmaur M; Baudouin V; Deschênes G; Macher MA; Loirat C
Pediatr Nephrol; 2011 Mar; 26(3):419-24. PubMed ID: 21188423
[TBL] [Abstract][Full Text] [Related]
44. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes.
Reynolds R; Hartnett ME; Atkinson JP; Giclas PC; Rosner B; Seddon JM
Invest Ophthalmol Vis Sci; 2009 Dec; 50(12):5818-27. PubMed ID: 19661236
[TBL] [Abstract][Full Text] [Related]
45. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
[TBL] [Abstract][Full Text] [Related]
46. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
Regunathan-Shenk R; Avasare RS; Ahn W; Canetta PA; Cohen DJ; Appel GB; Bomback AS
Am J Kidney Dis; 2019 Mar; 73(3):316-323. PubMed ID: 30413277
[TBL] [Abstract][Full Text] [Related]
47. Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency.
Vernon KA; Goicoechea de Jorge E; Hall AE; Fremeaux-Bacchi V; Aitman TJ; Cook HT; Hangartner R; Koziell A; Pickering MC
Am J Kidney Dis; 2012 Jul; 60(1):121-5. PubMed ID: 22503529
[TBL] [Abstract][Full Text] [Related]
48. The role of complement in C3 glomerulopathy.
Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R
Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733
[TBL] [Abstract][Full Text] [Related]
49. Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure.
Ali A; Schlanger L; Nasr SH; Sethi S; Gorbatkin SM
Am J Kidney Dis; 2016 Mar; 67(3):479-82. PubMed ID: 26704376
[TBL] [Abstract][Full Text] [Related]
50. Redefining C3 glomerulopathy: 'C3 only' is a bridge too far.
Larsen CP; Walker PD
Kidney Int; 2013 Feb; 83(2):331-2. PubMed ID: 23364589
[No Abstract] [Full Text] [Related]
51. The authors reply:
Servais A; Noel LH; Lesavre P; Frémeaux-Bacchi V
Kidney Int; 2013 Feb; 83(2):332-3. PubMed ID: 23364592
[No Abstract] [Full Text] [Related]
52. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.
Bomback AS; Appel GB
Nat Rev Nephrol; 2012 Nov; 8(11):634-42. PubMed ID: 23026947
[TBL] [Abstract][Full Text] [Related]
53. C3 glomerulopathy and current dilemmas.
Ito N; Ohashi R; Nagata M
Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
[TBL] [Abstract][Full Text] [Related]
54. A case of dense deposit disease associated with a group A streptococcal infection without the involvement of C3NeF or complement factor H deficiency.
Suga K; Kondo S; Matsuura S; Kinoshita Y; Kitano E; Hatanaka M; Kitamura H; Hidaka Y; Oda T; Kagami S
Pediatr Nephrol; 2010 Aug; 25(8):1547-50. PubMed ID: 20221776
[TBL] [Abstract][Full Text] [Related]
55. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
56. C3 Glomerulopathy: Pathogenesis and Treatment.
Ahmad SB; Bomback AS
Adv Chronic Kidney Dis; 2020 Mar; 27(2):104-110. PubMed ID: 32553242
[TBL] [Abstract][Full Text] [Related]
57. Complement and glomerular disease: new insights.
Pickering M; Cook HT
Curr Opin Nephrol Hypertens; 2011 May; 20(3):271-7. PubMed ID: 21422921
[TBL] [Abstract][Full Text] [Related]
58. Complete functional characterization of disease-associated genetic variants in the complement factor H gene.
Merinero HM; García SP; García-Fernández J; Arjona E; Tortajada A; Rodríguez de Córdoba S
Kidney Int; 2018 Feb; 93(2):470-481. PubMed ID: 28941939
[TBL] [Abstract][Full Text] [Related]
59. C3 glomerulonephritis associated with a missense mutation in the factor H gene.
Sugimoto K; Fujita S; Miyazaki K; Okada M; Takemura T
Tohoku J Exp Med; 2012 Jul; 227(3):211-5. PubMed ID: 22790979
[TBL] [Abstract][Full Text] [Related]
60. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS).
Sethi S; Fervenza FC
Semin Thromb Hemost; 2014 Jun; 40(4):416-21. PubMed ID: 24799306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]